Evidence map›Paper›PMID 40321705›Full record

ArticleClinical parkinsonism & related disorders2025

Impact of istradefylline on motor and non-motor symptoms in patients with Parkinson's disease: Subanalysis of the ISTRA ADJUST PD.

Hiroshi Nagayama, Osamu Kano, Renpei Sengoku, Naotake Yanagisawa, Asako Yoritaka, Keisuke Suzuki, Noriko Nishikawa, Yohei Mukai, Kyoichi Nomura, Norihito Yoshida and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Involvement of Adenosine ABrain and behavior · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Hiroshi NagayamaDepartment of Neurofunctional Science, Nippon Medical School, Tokyo, Japan.
Osamu KanoDepartment of Neurology, Toho University Faculty of Medicine, Tokyo, Japan.
Renpei SengokuDepartment of Neurology, Daisan Hospital, The Jikei University School of Medicine, Tokyo, Japan.
Naotake YanagisawaMedical Technology Innovation Center, Juntendo University, Tokyo, Japan.
Asako YoritakaDepartment of Neurology, Juntendo University Koshigaya Hospital, Saitama, Japan.
Keisuke SuzukiDepartment of Neurology, Dokkyo Medical University Hospital, Tochigi, Japan.
Noriko NishikawaDepartment of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Yohei MukaiDepartment of Neurology, National Center of Neurology and Psychiatry, Tokyo, Japan.
Kyoichi NomuraDepartment of Neurology, Higashimatsuyama Municipal Hospital, Saitama, Japan.
Norihito YoshidaDepartment of Neurology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Morinobu SekiDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.
Miho Kawabe MatsukawaDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Hiroo TerashiDepartment of Neurology, Tokyo Medical University, Tokyo, Japan.
Katsuo KimuraDepartment of Neurology, Yokohama City University Medical Center, Yokohama, Japan.
Jun TashiroSapporo Parkinson MS Neurological Clinic, Sapporo, Japan.
Shigeki HiranoDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hidetomo MurakamiDepartment of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
Hideto JokiDepartment of Neurology, National Hospital Organization Yokohama Medical Center, Yokohama, Japan.
Tsuyoshi UchiyamaDepartment of Neurology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Hideki ShimuraDepartment of Neurology, Juntendo University Koshigaya Hospital, Saitama, Japan.
Kotaro OgakiDepartment of Neurology, Juntendo University Urayasu Hospital, Chiba, Japan.
Jiro FukaeDepartment of Neurology, Juntendo University Nerima Hospital, Tokyo, Japan.
Yoshio TsuboiDepartment of Neurology, Fukuoka University, Fukuoka, Japan.
Kazushi TakahashiDepartment of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.
Toshimasa YamamotoDepartment of Neurology, Saitama Medical University, Saitama, Japan.
Kenichi KaidaDepartment of Neurology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Ryoko IharaDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Kazutomi KanemaruDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Taku HatanoDepartment of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Parkinson's disease (PD) presents with diverse motor and non-motor symptoms, some of which do not fully respond to dopamine replacement therapy. To clarify the effects of the adenosine A Methods: Patients with PD experiencing wearing-off with levodopa at 300-400 mg/day were randomized 1:1 to receive IST or no IST (control). Levodopa doses were titrated according to clinical severity throughout the study. PD symptoms were assessed using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Parkinson's Disease Questionnaire-39 (PDQ-39). Results: The efficacy analyses included 105 patients (IST, n = 52; control, n = 53). Regarding MDS-UPDRS subitems in patients in the IST group, significant improvements ( Conclusion: IST can improve motor and non-motor symptoms and quality of life suggesting that it provides more comprehensive improvement in PD symptoms than increasing the levodopa dose alone. Clinical trial registration: Japan Registry of Clinical Trials; study ID: jRCTs031180248.

Indexed as

Adenosine A2A receptor antagonistIstradefyllineLevodopaMotor symptomsNon-motor symptomsParkinson’s disease

Identifiers

PMID40321705
PMCPMC12049841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.